South Korea-based SK Biopharmaceuticals has collaborated with an artificial intelligence-driven biopharmaceutical firm, twoXAR, for the discovery and development of products to treat non-small cell lung cancer, it was reported yesterday.

According to the terms of the deal, twoXAR will implement its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms of action. Upon completion of screening, SK Biopharmaceuticals will use its internal AI Drug Design technology to advance a lead candidate and then carry out IND-enabling studies.

SK will hold exclusive worldwide rights for the development and commercialisation of any drug candidate. twoXAR will received an upfront payment and will receive development and commercial milestone payments and royalties.